Navigation Links
Biovista Inc. Announces Positive Efficacy Results in a Pre-clinical Trial of its BVA-201 Repositioned Drug for Multiple Sclerosis
Date:9/9/2009

CHARLOTTESVILLE, Virginia, September 9 /PRNewswire/ -- Biovista Inc. today announced that BVA-201, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-201 is an existing drug that Biovista repositioned in MS and is aimed at neuroprotection. It was shown to have both efficacy in reducing symptoms and no toxic effects in this well established model of MS.

"This is our second success in MS in a period of 6 months, with BVA-201 showing efficacy levels closely comparable to those of dexamethasone," said Aris Persidis, Ph.D., President of Biovista. "Histology results are also encouraging, since they seem to confirm our expectations regarding the compound's mechanism of action. What is even more important is that BVA-201 has a known and very favorable safety profile and is already approved for chronic use," Dr. Persidis added.

For a non-confidential information pack on BVA-201 contact Biovista at info@biovista.com.

About Biovista's BVA-201 trial in the MS EAE-MOG model

MS is a chronic inflammatory neurological disease. It is the most frequent non-traumatic disabling neurologic disease among young adults, with over 2.5 million patients worldwide. In the animal proof-of-concept trial, BVA-201 was compared to dexamethasone, a potent anti-inflammatory and immunosuppressive drug that is efficient in accelerating the recovery from MS relapses but too toxic for chronic use. BVA-201 induced a statistically significant reduction of EAE severity, the magnitude of which was directly comparable to that caused by dexamethasone. Furthermore, BVA-201 protected neural axons and
'/>"/>

SOURCE Biovista Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
2. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
3. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
4. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
5. Medivation Announces Participation in Upcoming Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section
8. Verenium Announces Reverse Stock Split to Take Effect September 9
9. BPG Properties, Ltd. Announces 2750 Morris Road in Lansdale, Pennsylvania is for Sale
10. American Oriental Bioengineering Announces September Investor Conferences Participation
11. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... antibody-drug conjugates for cancer, today announced the appointment of Thomas ... Reynolds has over 20 years, development experience gained in the ... Genetics. "I am delighted to welcome Tom at ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Two champions ... continued their sponsorship of an annual competition for middle ... and access to, innovative STEM study. The competition presents ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2
... On Thursday, December 9th, Mediaplanet published ... spearheading an industry-wide call to action advocating consumer ... us confront society,s most pressing challenges. By teaming ... Mediaplanet ,s ,Biotechnology, encourages appropriate policy action and ...
... China-Biotics, Inc. ("China-Biotics" or "the Company"), (Nasdaq: ... probiotics products in China, today announced that it has ... promissory notes for cash two days before the December ... notes were originally issued on December 11, 2007. The ...
... 8, 2010 Martek Biosciences Corporation (Nasdaq: MATK ... and fiscal year ended October 31, 2010. Total revenues for ... fourth quarter of fiscal 2009. Fourth quarter non-GAAP earnings per ... diluted share in last year,s fourth quarter.  For the full ...
Cached Biology Technology:The Biotechnology Industry Organization and Critical Path Institute Partner With Mediaplanet, Biocom, and the University of California Office to Spotlight the Science That Is Healing, Fueling and Feeding Our Global Population 2China-Biotics Announces Redemption of $25 million in Senior Convertible Notes 2China-Biotics Announces Redemption of $25 million in Senior Convertible Notes 3Martek Announces Fourth Quarter and FY 2010 Financial Results 2Martek Announces Fourth Quarter and FY 2010 Financial Results 3Martek Announces Fourth Quarter and FY 2010 Financial Results 4Martek Announces Fourth Quarter and FY 2010 Financial Results 5Martek Announces Fourth Quarter and FY 2010 Financial Results 6Martek Announces Fourth Quarter and FY 2010 Financial Results 7Martek Announces Fourth Quarter and FY 2010 Financial Results 8Martek Announces Fourth Quarter and FY 2010 Financial Results 9Martek Announces Fourth Quarter and FY 2010 Financial Results 10Martek Announces Fourth Quarter and FY 2010 Financial Results 11Martek Announces Fourth Quarter and FY 2010 Financial Results 12
(Date:4/23/2014)... TX (4/23/14) -- Researchers have found evidence of ... factors that increase aggressive behavior in children, especially ... not all children exposed to prenatal smoking will ... will not," said Brian Boutwell, Assistant Professor at ... and senior author on the study. "One ...
(Date:4/23/2014)... manufacturers are turning away from using triclosan as an ... health concerns. And now scientists are reporting new evidence ... in the ACS journal Chemical Research in Toxicology ... substance called octylphenol, promoted the growth of human breast ... in mice. , Kyung-Chul Choi and colleagues note that ...
(Date:4/23/2014)... to date of the family of bacteria that ... strategies and reveals surprising findings about the bacteria,s ... public health strategies to control this respiratory disease, ... Genomic analysis of 343 strains of the ... collected over the last 100 years illustrates how ...
Breaking Biology News(10 mins):Genetics risk, prenatal smoking may predict behavioral problems 2In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2Impact of whooping cough vaccination revealed 2
... researcher, please contact the Communications and External Relations staff member ... on ORNL and its research and development activities, please refer ... general media-related question or comment, you can send it to ... fuel pellets . . . Oak Ridge ...
... Spain: The numbers of cycles of preimplantation genetic diagnosis ... 2,700 reported in 2004 (the most recent year for ... screen for a growing number of genetically related conditions, ... the targeted condition are available for transfer and the ...
... that gladdens a mother,s heart also lights up the reward ... in a report that appears in the journal Pediatrics ... out the special mother-infant bond and how it sometimes go ... BCM and Texas Children,s Hospital and a research associate in ...
Cached Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 3Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 2Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 3A baby's smile is a natural high 2
...
... Gel loading buffer is especially formulated for ... nucleic acids. The gel loading solution contains ... to add density and facilitate sample loading. ... that require divalent cations and SDS has ...
... HPLC systems. , Integrated Instrument Control , ... EZChrom Elite can be configured with ... This provides a completely integrated system to control instrument's operation, collect ... ...
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
Biology Products: